Association of Mortality and Risk of Epilepsy With Type of Acute Symptomatic Seizure After Ischemic Stroke and an Updated Prognostic Model.


Journal

JAMA neurology
ISSN: 2168-6157
Titre abrégé: JAMA Neurol
Pays: United States
ID NLM: 101589536

Informations de publication

Date de publication:
01 06 2023
Historique:
pmc-release: 10 04 2024
medline: 14 6 2023
pubmed: 11 4 2023
entrez: 10 4 2023
Statut: ppublish

Résumé

Acute symptomatic seizures occurring within 7 days after ischemic stroke may be associated with an increased mortality and risk of epilepsy. It is unknown whether the type of acute symptomatic seizure influences this risk. To compare mortality and risk of epilepsy following different types of acute symptomatic seizures. This cohort study analyzed data acquired from 2002 to 2019 from 9 tertiary referral centers. The derivation cohort included adults from 7 cohorts and 2 case-control studies with neuroimaging-confirmed ischemic stroke and without a history of seizures. Replication in 3 separate cohorts included adults with acute symptomatic status epilepticus after neuroimaging-confirmed ischemic stroke. The final data analysis was performed in July 2022. Type of acute symptomatic seizure. All-cause mortality and epilepsy (at least 1 unprovoked seizure presenting >7 days after stroke). A total of 4552 adults were included in the derivation cohort (2547 male participants [56%]; 2005 female [44%]; median age, 73 years [IQR, 62-81]). Acute symptomatic seizures occurred in 226 individuals (5%), of whom 8 (0.2%) presented with status epilepticus. In patients with acute symptomatic status epilepticus, 10-year mortality was 79% compared with 30% in those with short acute symptomatic seizures and 11% in those without seizures. The 10-year risk of epilepsy in stroke survivors with acute symptomatic status epilepticus was 81%, compared with 40% in survivors with short acute symptomatic seizures and 13% in survivors without seizures. In a replication cohort of 39 individuals with acute symptomatic status epilepticus after ischemic stroke (24 female; median age, 78 years), the 10-year risk of mortality and epilepsy was 76% and 88%, respectively. We updated a previously described prognostic model (SeLECT 2.0) with the type of acute symptomatic seizures as a covariate. SeLECT 2.0 successfully captured cases at high risk of poststroke epilepsy. In this study, individuals with stroke and acute symptomatic seizures presenting as status epilepticus had a higher mortality and risk of epilepsy compared with those with short acute symptomatic seizures or no seizures. The SeLECT 2.0 prognostic model adequately reflected the risk of epilepsy in high-risk cases and may inform decisions on the continuation of antiseizure medication treatment and the methods and frequency of follow-up.

Identifiants

pubmed: 37036702
pii: 2802972
doi: 10.1001/jamaneurol.2023.0611
pmc: PMC10087089
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

605-613

Auteurs

Lucia Sinka (L)

Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.

Laura Abraira (L)

Epilepsy Unit, Department of Neurology, Vall d'Hebron Hospital Universitari, Barcelona, and Universitat Autonoma de Barcelona, Bellaterra, Spain.

Lukas L Imbach (LL)

Swiss Epilepsy Center, Klinik Lengg, Zurich, Switzerland.

Dominik Zieglgänsberger (D)

Department of Neurology, Kantonsspital St. Gallen, St Gallen, Switzerland.

Estevo Santamarina (E)

Epilepsy Unit, Department of Neurology, Vall d'Hebron Hospital Universitari, Barcelona, and Universitat Autonoma de Barcelona, Bellaterra, Spain.

José Álvarez-Sabín (J)

Epilepsy Unit, Department of Neurology, Vall d'Hebron Hospital Universitari, Barcelona, and Universitat Autonoma de Barcelona, Bellaterra, Spain.

Carolina Ferreira-Atuesta (C)

Department of Clinical & Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, United Kingdom.
Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York.
Chalfont Centre for Epilepsy, Chalfont St Peter, United Kingdom.

Mira Katan (M)

Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.
Department of Neurology, University Hospital and University of Basel, Basel, Switzerland.

Natalie Scherrer (N)

Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.

Giulio Bicciato (G)

Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.

Robert Terziev (R)

Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.

Cyril Simmen (C)

Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.

Kai Michael Schubert (KM)

Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.

Adham Elshahabi (A)

Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.

Christian R Baumann (CR)

Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.

Nico Döhler (N)

Department of Neurology, Kantonsspital St. Gallen, St Gallen, Switzerland.
Specialist Clinic for Neurorehabilitation, Kliniken Beelitz, Beelitz-Heilstätten, Germany.

Barbara Erdélyi-Canavese (B)

Department of Neurology, Kantonsspital St. Gallen, St Gallen, Switzerland.

Ansgar Felbecker (A)

Department of Neurology, Kantonsspital St. Gallen, St Gallen, Switzerland.

Philip Siebel (P)

Department of Neurology, Kantonsspital St. Gallen, St Gallen, Switzerland.

Michael Winklehner (M)

Department of Neurology 1, Kepler Universitätsklinikum, Neuromed Campus, Linz, Austria.
Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna, Austria.

Tim J von Oertzen (TJ)

Department of Neurology 1, Kepler Universitätsklinikum, Neuromed Campus, Linz, Austria.

Judith N Wagner (JN)

Department of Neurology 1, Kepler Universitätsklinikum, Neuromed Campus, Linz, Austria.

Gian Luigi Gigli (GL)

Department of Medicine, University of Udine and Clinical Neurology, Udine University Hospital, Udine, Italy.

Anna Serafini (A)

Department of Medicine, University of Udine and Clinical Neurology, Udine University Hospital, Udine, Italy.

Annacarmen Nilo (A)

Department of Medicine, University of Udine and Clinical Neurology, Udine University Hospital, Udine, Italy.

Francesco Janes (F)

Department of Medicine, University of Udine and Clinical Neurology, Udine University Hospital, Udine, Italy.

Giovanni Merlino (G)

Department of Medicine, University of Udine and Clinical Neurology, Udine University Hospital, Udine, Italy.

Mariarosaria Valente (M)

Department of Medicine, University of Udine and Clinical Neurology, Udine University Hospital, Udine, Italy.

María Paula Zafra-Sierra (MP)

Department of Neurology, Fundación Santa Fe de Bogotá, Universidad de Los Andes, Universidad del Bosque, Bogotá, Colombia.

Hernan Bayona-Ortiz (H)

Department of Neurology, Fundación Santa Fe de Bogotá, Universidad de Los Andes, Universidad del Bosque, Bogotá, Colombia.

Julian Conrad (J)

Department of Neurology, University of Muenster, Muenster, Germany.
Department of Neurology and German Center for Vertigo and Balance Disorders-IFB-LMU, Ludwig Maximilians University of Munich, Munich, Germany.

Stefan Evers (S)

Department of Neurology, University of Muenster, Muenster, Germany.
Department of Neurology, Krankenhaus Lindenbrunn, Coppenbrügge, Germany.

Piergiorgio Lochner (P)

Department of Neurology, Saarland University Medical Center, Homburg, Germany.

Frauke Roell (F)

Department of Neurology, Saarland University Medical Center, Homburg, Germany.

Francesco Brigo (F)

Department of Neurology, Hospital of Merano (SABES-ASDAA), Merano-Meran, Italy.

Carla Bentes (C)

Department of Neurosciences and Mental Health (Neurology), Hospital de Santa Maria-CHLN, Centro de Estudos Egas Moniz, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.

Ana Rita Peralta (AR)

Department of Neurosciences and Mental Health (Neurology), Hospital de Santa Maria-CHLN, Centro de Estudos Egas Moniz, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.

Teresa Pinho E Melo (T)

Department of Neurosciences and Mental Health (Neurology), Hospital de Santa Maria-CHLN, Centro de Estudos Egas Moniz, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.

Mark R Keezer (MR)

Stichting Epilepsie Instellingen Nederland (SEIN), Heemstede, the Netherlands.
Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.

John S Duncan (JS)

Department of Clinical & Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, United Kingdom.
Chalfont Centre for Epilepsy, Chalfont St Peter, United Kingdom.

Josemir W Sander (JW)

Department of Clinical & Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, United Kingdom.
Chalfont Centre for Epilepsy, Chalfont St Peter, United Kingdom.
Stichting Epilepsie Instellingen Nederland (SEIN), Heemstede, the Netherlands.

Barbara Tettenborn (B)

Department of Neurology, Kantonsspital St. Gallen, St Gallen, Switzerland.

Matthias J Koepp (MJ)

Department of Clinical & Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, United Kingdom.
Chalfont Centre for Epilepsy, Chalfont St Peter, United Kingdom.

Marian Galovic (M)

Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.
Department of Clinical & Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, United Kingdom.
Chalfont Centre for Epilepsy, Chalfont St Peter, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH